Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Minerva Neurosciences, Inc.NASDAQ: NERV
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities rises 450133.7% from a year ago
Other current liabilities stood at $3.96B at the end of Q2 FY2026, up 450133.7% from a year earlier and up 200999.6% from the prior quarter.
Context
- Other current liabilities amounted to 4.2% of total assets at the end of Q2 FY2026, up 1.3 pp from a year earlier.
- Other current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +450133.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- (473) USD
- Year-over-year change
- -100.1%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (473) | -100.1% |
| FY2024 | 2024-12-31 | 363.18K | -38.5% |
| FY2023 | 2023-12-31 | 590.77K | +3883.1% |
| FY2022 | 2022-12-31 | 14.83K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's Jun 2026 other current liabilities of $3.96B is the highest of the 4 companies compared; the peer median is $1.89M.
- Its year-over-year change of +450133.7% is the highest of 4, against a peer median of +1229.6%.
- Other current liabilities amounts to 4.2% of total assets for NERV, versus a peer median of 2.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $3.96B | +450133.7% | — | 4.2% | |
NRXSNeurAxis, Inc. | Mar 2026 | $2.31M | +31389.5% | -22.9% | 26.4% |
| Dec 2025 | $1.89M | +1229.6% | — | 0.1% | |
| Mar 2026 | $1.41M | +46.0% | -32.3% | 2.6% | |
| Peer median (excluding NERV) | $1.89M | +1229.6% | -27.6% | 2.6% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.76M | 36.09M | 40.91M | 21.36M | 82.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 100K | 4.07M | 1.09M | 906.9K | 798K |
| Total Current Assets | 62.2M | 40.16M | 42M | 22.27M | 83.1M |
| Property, Plant & Equipment (Net) | 51.08K | 16.33K | 10.88K | 5.44K | 0 |
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M |
| Intangible Assets | 0 | 42.57K | 17.03K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 14.92M | 14.93M | 14.9M | 14.87M | 14.87M |
| Total Assets | 77.12M | 55.09M | 56.9M | 37.14M | 97.97M |
| Account Payables | 1.85M | 969.67K | 1.81M | 1.61M | 639K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 14.83K | 590.77K | 363.18K | (473) |
| Total Current Liabilities | 2.82M | 1.38M | 3.34M | 2.84M | 2.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 64.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 66.33M | 73.73M | 82.02M | 60M | 171.46M |
| Total Non-current Liabilities | 66.33M | 73.73M | 82.02M | 60M | 236.43M |
| Total Liabilities | 69.15M | 75.11M | 85.36M | 62.84M | 238.72M |
| Common Stock | 534 | 534 | 699 | 699 | 4.33K |
| Retained Earnings | (334.7M) | (366.81M) | (396.82M) | (395.38M) | (688.8M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.98M | (20.02M) | (28.46M) | (25.69M) | (140.75M) |
| Total Debt | 0 | 0 | 0 | 0 | 64.96M |
| Net Debt | (60.76M) | (36.09M) | (40.91M) | (21.36M) | (17.34M) |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.